Navigation Links
Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
Date:5/3/2013

SAN DIEGO, May 3, 2013 /PRNewswire/ -- Ambrx today entered into a collaboration agreement with Bristol-Myers Squibb (NYSE: BMY) for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.

Under terms of the agreement, Ambrx will receive an upfront payment of $15 million, funding for discovery and research activities, and potential development, regulatory and sales based milestone payments of up to $97 million per product resulting from the collaboration. Bristol- Myers Squibb will receive worldwide rights to develop and commercialize products resulting from the collaboration, and Ambrx is eligible to receive royalties on net sales. Additional terms were not disclosed.

"Bristol-Myers Squibb is a global biopharmaceutical leader with expertise developing and commercializing novel medicines for the treatment of cancer and other diseases, and we are pleased to enter into a third collaboration with the company to include another aspect of our technology platform," said Lawson Macartney , Ph.D., chief executive officer of Ambrx. "We look forward to working together to further utilize Ambrx's technology to discover and advance these antibody drug conjugates for oncology indications."

Ambrx and Bristol-Myers Squibb entered into two separate agreements in September 2011 to research, develop and commercialize biologics created with Ambrx's protein medicinal chemistry technology. These therapeutic candidates, which target the Fibroblast Growth Factor 21 (FGF-21) protein for the potential treatment of type 2 diabetes, and the Relaxin hormone for the potential treatment of heart failure, are being developed by Bristol-Myers Squibb.

About Ambrx
Ambrx Inc. is a clinical stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, including antibody drug conjugates, bispecific antibodies and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed Phase 2b clinical trials. In addition to its three collaborations with Bristol-Myers Squibb, Ambrx has collaborations to discover and develop products incorporating Ambrx technology with Astellas, Merck, Eli Lilly and Company and several undisclosed companies.  Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas.  For additional information, visit www.ambrx.com.

Media Contacts:
Ian Stone
(619) 308-6541

David Schull
(212) 845-4271


'/>"/>
SOURCE Ambrx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
6. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
7. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
8. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
9. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
10. Empire Asset Management Co. Initiates Coverage on Transcept Pharmaceuticals Inc., (NASDAQ: TSPT)
11. Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017 /PRNewswire/ ... announced today the partnership of their 3D body ... in healthcare IT.  The new integration will be ... on an interactive model of the human body. ... data saves clinicians time, while also increasing the ...
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... announced that executive management will participate in the RBC ... 22-23, 2017. Adrian Adams , Chief Executive Officer, ... p.m. local time on Wednesday, February 22, 2017. ... event may be accessed from the Investors section of ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... February 18, 2017 , ... ... the latest information and contact points to easily connect elderly veterans of America's ... living, and elder-care funding. It also conveys material on this year's increase in ...
(Date:2/17/2017)... ... 2017 , ... While EHR data has revolutionized the nursing ... workstation designed to reduce nursing fatigue while enhancing productivity. Based on field experience ... lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. , Nurses ...
(Date:2/17/2017)... ... 17, 2017 , ... Wells Pharmacy Network offers physicians WellsPx3, ... and non-controlled substances plus the ability to manage orders on their desktop or ... accept electronic prescriptions, according to the Office of the National Coordinator of Health ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Webinar**, Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, ... be asking before selecting an FDA approval pathway? , How should they ...
(Date:2/17/2017)... ... 17, 2017 , ... Corrective Action & Preventive Action for ... Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/capamd      ... action (PA)? , The methods share techniques and tools but they are different ...
Breaking Medicine News(10 mins):